Clinical Trial Update: Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue [Phase 3]

View source ↗

Summary

Phase 3 study evaluating a formulated methylene blue for inoperable, radiotherapy-unfit advanced basal cell carcinoma (including morpheaform, noduloulcerative, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Formulated Methylene Blue (methylene blue)

Snippet

Sponsor: Daryoush Hamidi Alamdari, PhD | Conditions: Advanced Basal Cell Carcinoma (BCC), Inoperable Disease | Phase 3 | Status: ENROLLING_BY_INVITATION